BioCure

BioCure

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5.0M

Overview

BioCure is a private, likely revenue-generating biotechnology company based in Peachtree Corners, Georgia, focusing on advanced polymer-based medical devices. The company's core competency lies in custom-engineered PVA hydrogels and amphiphilic block copolymers, which are applied across three primary areas: active drug delivery, implantable devices, and dermal barriers. With a foundation built on decades of PVA experience, BioCure operates through a hybrid business model of proprietary product development (like Bead Block) and collaborative R&D/manufacturing services for other companies. Its primary markets are in oncology and interventional medicine, with potential expansion into broader immunology and dermatology sectors.

OncologyImmunology

Technology Platform

Expertise in custom Polyvinyl Alcohol (PVA) hydrogels and amphiphilic block copolymers for creating biocompatible, in-situ forming implants, drug delivery depots, and dermal membranes.

Funding History

2
Total raised:$5.0M
Seed$4.8M
Grant$200K

Opportunities

Large and growing markets in targeted drug delivery (especially for biologics), interventional oncology, and advanced wound care present significant opportunities.
The company's in-situ forming technology enables minimally invasive procedures, aligning with key healthcare trends towards outpatient and less traumatic interventions.

Risk Factors

Key risks include the long and costly regulatory pathway for implantable medical devices, competition from larger established medtech firms, and dependence on successful commercialization of platform-derived products beyond the flagship Bead Block implant.
As a private company, access to sufficient capital for scaling is also a perennial risk.

Competitive Landscape

BioCure competes in the advanced biomaterials space against large medical device companies (e.g., BD, Boston Scientific) with hydrogel offerings, specialty drug delivery companies, and other innovative startups. Its differentiation lies in its deep, specific expertise in PVA chemistry and its proven ability to translate that into a commercial, best-in-class embolic product.